Research and Development (R&D) Strategy of Execellence
We leverage our knowledge of pathophysiological processes and disease characteristics to pioneer new potential treatments. There’s more to come as we continue to chase the possibilities and strive to make a difference for patients everywhere.
Geventis R&D is driven by the potential to transform the lives of patients. We work in disease areas with some of the greatest unmet need. We work relentlessly, knowing that bold new possibilities await discovery. As a leading global biotechnology company, we work toward those once-in-a-lifetime moments that could become a historic point in our pursuit of innovative treatments.
Do you believe each day holds boundless
Our Disease Areas
Cardiovascular Disease
CVRM (Cardiovascular, Renal and Metabolism) is one of our main therapy areas because science continues to uncover commonalities between metabolism, heart failure, arterial vascular disease and renal disease – four distinct but interrelated areas.
Vaccines and Infectious Diseases
As a biotechnology company, Genventis scientists have been dedicated since our founding in 2023 to addressing some of the world’s most urgent health challenges — including HIV/AIDS, Zika virus, Ebola, and COVID-19. Our mission is to advance the development of innovative medicines and vaccines to help prevent and treat the most infectious diseases worldwide.
Ophthalmology
Our Ophthalmology research program is focused on discovering and developing innovative treatments for vision-threatening conditions, including age-related macular degeneration, glaucoma, diabetic retinopathy, and rare ocular diseases.
R&D Technologies
With capabilities in multiple drug modalities, including small molecules, protein therapeutics, antisense oligonucleotides and gene therapy, Genventis pursues the most appropriate modality for each target.
Small Molecules
Small molecule therapeutics are often taken orally as a pill and can readily distribute into cells and tissues, which differentiates them from other modalities. Medicinal chemists aim to optimize the potency of starting molecules toward the desired biological target along with physical properties to maximize the potential of the medicine to treat disease.
.jpg)
Protein Therapeutics
Therapeutic proteins, also referred to as biologics, are often as much as a thousand times the size of small-molecule drugs. Although this type of drug is much more complicated to make and characterize, using biologics allows scientists to attack serious disease in ways that might not be possible with other technologies.
Antisense Oligonucleotides
Antisense oligonucleotides (ASOs) are synthetic, single-stranded nucleic acids consisting of eight to 50 nucleotides which bind to RNA and are designed to interfere with target gene expression. ASOs utilize several distinct mechanisms to alter RNA and either restore desired protein expression or reduce and modify toxic proteins.
.jpg)
Cell Therapy
Autologous cell therapies have demonstrated strong clinical benefit, but their complex and individualized manufacturing limits broad accessibility. Early efforts in allogeneic therapies have faced challenges, particularly with cell persistence and durability.
Antibody Drug Conjugates
At BeOne, we are developing next-generation antibody-drug conjugates (ADCs)—targeted therapies that deliver potent anti-cancer drugs directly to tumor cells. By combining a tumor-targeting antibody with a cytotoxic payload, ADCs are designed to maximize cancer cell killing while minimizing harm to healthy tissues.
.jpg)
Monoclonal Antibodies
Monoclonal antibodies (mAbs) are specially designed proteins that recognize and attach to specific cellular targets. Once attached, they can either help the immune system destroy the cancer or block signals that the cancer cells need to grow and survive.
Partner With Us
We welcome the opportunity to explore working with other innovators. If your company or institution would like to share a potential asset or platform technology for collaboration, contact us today.
